Skip to product information
1 of 1

MICA Recombinant Rabbit mAb (SDT-1589-10)

MICA Recombinant Rabbit mAb (SDT-1589-10)

Catalog Number: S0B3559 Application: ELISA Reactivity: Human Conjugation: Unconjugated Brand: Starter
Price:
Regular price $1,195.00 SGD
Regular price Sale price $1,195.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen MICA
Synonyms MHC class I polypeptide-related sequence A; MIC-A; PERB11.1; MICA
Immunogen Recombinant Protein
Clone Number SDT-1589-10
Antibody Type Recombinant mAb
Isotype IgG
Application Sandwich ELISA
Reactivity Hu
Cross Reactivity

Cross with MICB

Purification Protein A
Concentration 2 mg/ml
Purity >90% by HPLC
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt, 2 to 8 °C as supplied

Background

MHC class I chain-related genes MICA and MICB are transmembrane glycoproteins that function as ligands for human NKG2D. The two proteins are highly related, sharing 85% amino acid identity, but are also polymorphic. Recognition of MICA or MICB by NKG2D results in the activation of NK cell cytolytic activity and/or cytokine production. MICA/B are minimally expressed on normal cells, but are frequently expressed on or shed from epithelial tumors and can be induced by bacterial and viral infections. MICA and MICB recognition is involved in tumor surveillance, viral infections, and autoimmune diseases. MICA/B proteins are downregulated by tumor cells via intriguing molecular mechanisms, such as post-translational modifications in which the external domains of MICA/B are proteolytically cleaved by surface proteases and shed into the extracellular space. MICA/B shedding by cancer cells causes effective escape from NKG2D recognition and allows the development of cancers. Patients frequently have increased concentrations of soluble MICA/B molecules shed in the blood plasmas and sera, thus indicating that MICA/B shedding is a therapeutic target in immune-oncology.

Picture

Paired Recommendations